Mengyuan Fu
Postdoctoral FellowAbout
Research
Publications
2026
Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review.
Li C, Fu M, Berg K, Wallach J, Ling K, Wei R, Shi L, Ross J, Guan X. Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review. Neurology 2026, 107: e218373. PMID: 42492033, PMCID: PMC13445500, DOI: 10.1212/wnl.0000000000218373.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDrug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics
Fu M, Wallach J, So A, Doernberg H, Li X, Guan X, Ramachandran R, Ross J. Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics. Health Affairs Scholar 2026, 4: qxag181. PMID: 42482967, PMCID: PMC13387065, DOI: 10.1093/haschl/qxag181.Peer-Reviewed Original ResearchNovel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks.
Fu M, Ghosh R, Taherifard E, Ramachandran R, Ross JS. Novel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks. JAMA Health Forum 2026, 7: e262340. PMID: 42536387, DOI: 10.1001/jamahealthforum.2026.2340.Peer-Reviewed Original ResearchEligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021
Ma Z, Zhang Y, Chen D, Fu M, Han K, Zhang Y, Ross J, Shi L, An Z, Guan X. Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021. Cancer 2026, 132: e70425. PMID: 42046201, DOI: 10.1002/cncr.70425.Peer-Reviewed Original ResearchConceptsPerformance statusClinical trialsCancer clinical trialsEligibility criteriaNational Medical Products AdministrationCancer drug trialsChina National Medical Products AdministrationAdult patientsCardiac functionProduct administrationDrug trialsOrgan functionTrial characteristicsNational Cancer Institute’s (NCIAnticancer drugsCancerTrialsExternal generalizabilityInternal validityRestriction criteriaMalignancyNoncomplianceNCIPatientsComorbiditiesPsychotropic medication prescribing for patients with insomnia comorbid with depressive or anxiety disorders in primary healthcare facilities in Beijing
Fu M, Li C, Zhou X, Gong Z, Zhu Y, Ding Y, Ling K, Wang F, Shi L, Guan X. Psychotropic medication prescribing for patients with insomnia comorbid with depressive or anxiety disorders in primary healthcare facilities in Beijing. BJPsych Open 2026, 12: e55. PMID: 41640068, PMCID: PMC12926887, DOI: 10.1192/bjo.2025.10967.Peer-Reviewed Original Research
2025
Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China
Gong Z, Fu M, Hu H, Li C, Ling K, Li H, Lin H, Shen P, Zhu D, Shi L, Guan X. Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China. Communications Medicine 2025, 5: 529. PMID: 41258442, PMCID: PMC12727714, DOI: 10.1038/s43856-025-01248-0.Peer-Reviewed Original ResearchStrength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner A, Ross J, Guan X. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology 2025, 26: 1252-1260. PMID: 40782821, DOI: 10.1016/s1470-2045(25)00329-8.Peer-Reviewed Original ResearchConceptsRandomised controlled trialsSingle-arm trialRisk of biasCancer drug indicationsRatio of hazard ratiosHigh risk of biasHigh riskStrength of evidenceRetrospective analysisNational Natural Science FoundationEffect sizeLow riskCancer drugsCancer drug approvalsLow risk of biasDrug efficacy dataRisk-of-bias assessmentChina National Knowledge Infrastructure databasesNational Knowledge Infrastructure databasesNovel cancer drugsDrug indicationsPivotal studiesProphylactic vaccinesNational Natural Science Foundation of ChinaClinical evidenceAnticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022
Fu M, Ling K, Gong Z, Dong S, Li H, Wang F, Xu Y, Shi L, Ross J, Guan X. Anticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022. Thrombosis Research 2025, 253: 109417. PMID: 40752480, DOI: 10.1016/j.thromres.2025.109417.Commentaries, Editorials and LettersRegulatory Review Time of Vaccine Approvals in China Between 2005 and 2024
Ding Y, Fu M, Ramachandran R, Shi L, Ross J, Guan X. Regulatory Review Time of Vaccine Approvals in China Between 2005 and 2024. JAMA Network Open 2025, 8: e2518255. PMID: 40587134, PMCID: PMC12210079, DOI: 10.1001/jamanetworkopen.2025.18255.Peer-Reviewed Original ResearchAccess to Information Cited in National Organization for Rare Disorders Reports
Fu M, Ling K, Zhou X, Dave S, Li C, Shi L, Guan X, Ross J. Access to Information Cited in National Organization for Rare Disorders Reports. JAMA Network Open 2025, 8: e2511758. PMID: 40397446, PMCID: PMC12096240, DOI: 10.1001/jamanetworkopen.2025.11758.Peer-Reviewed Original Research
News
Get In Touch
Contacts
Email